Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Miwa Haranaka"'
Autor:
Miwa Haranaka, Makoto Yono, Hiroyuki Kishino, Rie Igarashi, Nobuyuki Oshima, Miyuki Sawata, Heather Loryn Platt
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult pneumococcal disease after the introduction of pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly p
Externí odkaz:
https://doaj.org/article/64c4d25542704f7992181314d105a389
Autor:
Takuma Yonemura, Rie Yazawa, Miwa Haranaka, Kazuki Kawakami, Masayuki Takanuma, Takumi Kanzo, Dimitris Stefanidis, Yasumasa Arai
Publikováno v:
BMC Pharmacology and Toxicology, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background FKB327 has been developed as a biosimilar of the adalimumab reference product (RP). We compared the pharmacokinetics (PK), safety, and immunogenicity of FKB327 with those of the adalimumab RP after a single dose by subcutaneous (S
Externí odkaz:
https://doaj.org/article/eeebeba3510b413bb1922f2cbe0455e9
Autor:
Miwa Haranaka, James Baber, Yoichiro Ogama, Masako Yamaji, Masakazu Aizawa, Osamu Kogawara, Ingrid Scully, Eleni Lagkadinou, Ӧzlem Türeci, Uğur Şahin, Philip R. Dormitzer, William C. Gruber, Stephen Lockhart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Here the authors provide the interim analysis of an ongoing phase 1/2 study of the BNT162b2 vaccine in healthy Japanese adults. They report mainly mild to moderate local reactions and no serious adverse events as well as good antibody induction one m
Externí odkaz:
https://doaj.org/article/b46c9a1d119e4f05b2b58be147b5baa4
Autor:
Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida, Jiro Mukai, Kenji Furukawa, Seitaro Ohtsu, Susumu Nakade, Tomohiro Hikima, Miwa Haranaka, Naoto Uemura
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1967-1976 (2021)
Abstract Camostat mesylate, an oral serine protease inhibitor, is used to treat chronic pancreatitis and reflux esophagitis. Recently, camostat mesylate and its active metabolite 4‐(4‐guanidinobenzoyloxy)phenylacetic acid (GBPA) were reported to
Externí odkaz:
https://doaj.org/article/f1376106677341e6ac6e9becf4c1fc0c
Autor:
Shady Kotb, Miwa Haranaka, Nicolas Folschweiller, Phoebe Nakanwagi, Céline Verheust, Nathalie De Schrevel, Marie-Pierre David, Narcisa Mesaros, Veronica Hulstrøm
Publikováno v:
Respiratory Investigation. 61:261-269
Autor:
Miwa Haranaka, Takanori Tanaka, SungHyun Kim, YunJu Bae, DaBee Jeon, EunJin Choi, JungBin Cha, SangMi Lee, Yoichiro Ogama
Publikováno v:
Immunotherapy. 15:149-161
Aim: Comparing pharmacokinetics and safety of CT-P17 and EU-approved reference adalimumab (EU–adalimumab) in Japan. Materials & methods: Double-blind, parallel-group phase I trial at three hospitals. Healthy Japanese adults were randomized (1:1) to
Autor:
Anthony Dowell, Yaru Shi, Silvia Narejos Perez, Chih-Jen Chang, Miwa Haranaka, Tina M. Sterling, Howard I. Schwartz, Jose F. Cardona, Ulrike K. Buchwald, Luwy Musey, Heather L. Platt, Gretchen M. Tamms, Alison Pedley, L. Morgan, Ron Dagan
Publikováno v:
Vaccine. 40:162-172
Background Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCETM, Merck Sharp & Dohme Corp
Autor:
Naoto Noda, Tatsuto Hamatani, Yuta Shibue, Takeshi Takagaki, Atsushi Kitamura, Miwa Haranaka, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(10)
EPI-589 attenuates oxidative stress due to the radical scavenging activity of the reduced form and affects mitochondrial energy metabolism as a substrate of quinone-oxidoreductases. Given the effects of EPI-589 on oxidative stress and mitochondrial d
Autor:
Akira Wakamatsu, Atsushi Nakano, Masanari Shiramoto, Takashi Eto, Hirofumi Ogura, Keiko Hoyano, Miwa Haranaka, Shin Irie, Hiroko Ino, Takumi Terao
Publikováno v:
Clinical Pharmacology in Drug Development
Levocetirizine is classified as a second‐generation antihistamine. Levocetirizine is available for the treatment of allergic disorders such as allergic rhinitis and chronic idiopathic urticaria. This was a single‐center, single‐dose, open‐lab
Publikováno v:
American Journal of Cardiovascular Drugs
Background and Objective Dabigatran etexilate (DE) is an anticoagulant with proven efficacy and tolerability for stroke prevention in patients with non-valvular atrial fibrillation. For the commercial capsule, a complex formulation is used to maintai